Le J, Prensky W, Yip Y K, Chang Z, Hoffman T, Stevenson H C, Balazs I, Sadlik J R, Vilcek J
J Immunol. 1983 Dec;131(6):2821-6.
Human T cell hybridomas were established by fusion of SH9 cells, the 6-thioguanine-resistant mutant line of human T lymphoma Hut 102-B2, with concanavalin A-stimulated human peripheral blood lymphocytes. Hybridoma line L38 produced a macrophage activating factor (MAF) with the ability to activate human peripheral blood monocytes to show enhanced cytotoxicity against human colon adenocarcinoma HT-29 cells in a 72-hr 125iododeoxyuridine-release assay. The L38 line was then cloned by the limiting dilution technique and two sublines, L38B and L38D, were found to produce high levels of MAF constitutively. Interferon activity was also detected in L38B and L38D supernatants. When interferon activity was neutralized with specific antiserum to purified human immune interferon (IFN-gamma), MAF activity was abrogated. To confirm that the MAF activity is indeed due to IFN-gamma, IFN-gamma was purified from the culture supernatant of another human T cell hybridoma, L265K2, a cell line known to produce high levels of IFN-gamma. Two highly purified IFN-gamma fractions with m.w. of 20,000 and 25,000, respectively, were obtained by NaDodSO4/polyacrylamide gel electrophoresis (SDS-PAGE). Similar fractions were obtained from IFN-gamma derived from human peripheral blood lymphocyte (PBL) cultures induced with 12-0-tetradecanoylphorbol-13-acetate (TPA) and phytohemagglutinin (PHA). In comparison, Escherichia coli-derived recombinant human IFN-gamma separated by SDS-PAGE yielded two major active fractions with m.w. of 17,000 and 34,000. With all three types of preparations, a close correlation was found between the presence of IFN-gamma activity demonstrable in an antiviral assay and MAF activity in individual fractions. Substantial quantitative differences were observed in the ability of various human IFN to activate monocytes. Although no MAF activity was detected with IFN-alpha and IFN-beta at concentrations up to 200 U/ml, both natural and recombinant IFN-gamma showed marked MAF activity at concentrations as low as 0.3 to 1 U/ml.
人T细胞杂交瘤是通过将人T淋巴瘤Hut 102 - B2的6 - 硫鸟嘌呤抗性突变株SH9细胞与伴刀豆球蛋白A刺激的人外周血淋巴细胞融合而建立的。杂交瘤细胞系L38产生一种巨噬细胞激活因子(MAF),在一项72小时的125碘脱氧尿苷释放试验中,该因子能够激活人外周血单核细胞,使其对人结肠腺癌HT - 29细胞的细胞毒性增强。然后通过有限稀释技术对L38细胞系进行克隆,发现两个亚系L38B和L38D能组成性地产生高水平的MAF。在L38B和L38D的培养上清液中也检测到了干扰素活性。当用针对纯化的人免疫干扰素(IFN - γ)的特异性抗血清中和干扰素活性时,MAF活性被消除。为了证实MAF活性确实是由IFN - γ引起的,从另一种人T细胞杂交瘤L265K2(已知能产生高水平IFN - γ的细胞系)的培养上清液中纯化IFN - γ。通过十二烷基硫酸钠/聚丙烯酰胺凝胶电泳(SDS - PAGE)分别获得了两种分子量分别为20,000和25,000的高度纯化的IFN - γ组分。从用12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯(TPA)和植物血凝素(PHA)诱导的人外周血淋巴细胞(PBL)培养物中获得的IFN - γ也得到了类似的组分。相比之下,通过SDS - PAGE分离的大肠杆菌衍生的重组人IFN - γ产生了两种主要的活性组分,分子量分别为17,000和34,000。对于所有这三种类型的制剂,在抗病毒试验中可检测到的IFN - γ活性与各个组分中的MAF活性之间发现了密切的相关性。观察到不同的人干扰素激活单核细胞的能力存在显著的定量差异。虽然在浓度高达200 U/ml时未检测到IFN - α和IFN - β的MAF活性,但天然和重组的IFN - γ在低至0.3至1 U/ml的浓度下均显示出明显的MAF活性。